SubsidieMeestersClinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniae
VAXDYN is developing innovative vaccines targeting antimicrobial-resistant infections, starting with K-VAX for Klebsiella pneumoniae, to combat a critical global health threat.
Projectdetails
Introduction
VAXDYN, a Spanish biotech startup, is leading innovation with a novel vaccine platform targeting antimicrobial-resistant (AMR) infections, a critical global health threat. With projections indicating a potential cost of USD 100 trillion and over 10 million deaths by 2050 due to AMR, VAXDYN's work is of paramount importance. Their patented technology focuses on the most dangerous AMR bacteria, developing vaccines for four out of the six most urgent bacterial pathogens, which are responsible for 73% of AMR-related deaths worldwide.
Vaccine Platform
VAXDYN's vaccine platform stands out for its utilization of full Outer-Membrane Protein bacterial antigens with a safe carrier cell to stimulate immunity. This unique strategy has earned approval from European regulators and prestigious backers such as the CARB-X accelerator, funded by entities including the Bill and Melinda Gates Foundation and the Wellcome Trust.
Lead Vaccine: K-VAX
The company's lead vaccine, K-VAX, targets Klebsiella pneumoniae, the third leading cause of AMR deaths, claiming 700,000 lives annually. There are no current vaccines against this pathogen, which has a mortality rate exceeding 50%. VAXDYN's K-VAX aims to serve both the global elderly population and prevent neonatal sepsis in low- and middle-income countries, addressing a potential $6 billion market by 2035.
Clinical Trials and Future Plans
VAXDYN is advancing K-VAX through Phase 1A trials, supported by CARB-X and private investors. The next steps involve:
- Phase 1B trials
- Phase 2 trials to determine the final formulation and efficacy
EIC funds are crucial for these next steps. Post-trials, VAXDYN plans to license K-VAX, continuing the development of its second vaccine, P-VAX, for Pseudomonas aeruginosa infections in patients with chronic respiratory conditions. This strategic move underscores VAXDYN's commitment to addressing urgent health crises and leading in the AMR vaccine domain.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.494.748 |
| Totale projectbegroting | € 2.494.748 |
Tijdlijn
| Startdatum | 1-1-2025 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- VAXDYN SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Paragon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR)Immunethep's PNV vaccine targets and blocks immunosuppressive GAPDH from five bacteria, enhancing immune response and showing high efficacy and safety in preclinical trials. | EIC Accelerator | € 2.499.999 | 2023 | Details |
A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHODeveloping a combination of meropenem and ANT3310 to combat drug-resistant Gram-negative infections, aiming for market approval by 2029 and projected sales over €10bn in 13 years. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitisGedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance. | EIC Accelerator | € 2.499.999 | 2024 | Details |
TowArd demoCRatization Of ev-BAsed TherapiesEVerZom aims to revolutionize EV manufacturing with a patented scalable process, targeting GMP compliance and commercial production to lead the European market in clinical applications. | EIC Accelerator | € 1.700.000 | 2022 | Details |
Accelerating scale up and commercialisation of 100% bacteria free eggs for use in production of vaccinesOvagen seeks EIC Accelerator funding to mass-produce germ-free eggs for rapid vaccine production against COVID-19 and future pandemics, expanding on their OvaVax project's groundwork. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Paragon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR)
Immunethep's PNV vaccine targets and blocks immunosuppressive GAPDH from five bacteria, enhancing immune response and showing high efficacy and safety in preclinical trials.
A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO
Developing a combination of meropenem and ANT3310 to combat drug-resistant Gram-negative infections, aiming for market approval by 2029 and projected sales over €10bn in 13 years.
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis
Gedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance.
TowArd demoCRatization Of ev-BAsed Therapies
EVerZom aims to revolutionize EV manufacturing with a patented scalable process, targeting GMP compliance and commercial production to lead the European market in clinical applications.
Accelerating scale up and commercialisation of 100% bacteria free eggs for use in production of vaccines
Ovagen seeks EIC Accelerator funding to mass-produce germ-free eggs for rapid vaccine production against COVID-19 and future pandemics, expanding on their OvaVax project's groundwork.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
InnomABsIPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie. | Mkb-innovati... | € 14.888 | 2023 | Details |
Het Rapid Response Vaccinatieplatform: Snel een epidemie onder controle krijgen door een snellere en efficiëntere vaccinatiemethode.Het project ontwikkelt een Rapid Response Vaccinatie Platform dat mRNA-vaccins via micronaalden pijnvrij en kosteneffectief toedient, om snel uitbraken wereldwijd te bestrijden. | Mkb-innovati... | € 350.000 | 2020 | Details |
Development of a marketable adjuvant candidate for vaccine applicationsADJUVACCINE aims to validate a synthetic platform for scalable production of optimized saponin adjuvants to enhance cost-effective vaccines and attract investment for market entry. | ERC Proof of... | € 150.000 | 2023 | Details |
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered ProphagesPHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine. | ERC Starting... | € 1.500.000 | 2025 | Details |
PReclinical EVAluation and Investigation of Laterocidamide - A novel antibiotic from a new drug class to overcome polymyxin resistance.Project PREVAIL aims to validate the novel antibiotic Laterocidamide (LATERO) against polymyxin-resistant Gram-negative bacteria, addressing antibiotic resistance while exploring its commercial potential. | ERC Proof of... | € 150.000 | 2024 | Details |
InnomABs
IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.
Het Rapid Response Vaccinatieplatform: Snel een epidemie onder controle krijgen door een snellere en efficiëntere vaccinatiemethode.
Het project ontwikkelt een Rapid Response Vaccinatie Platform dat mRNA-vaccins via micronaalden pijnvrij en kosteneffectief toedient, om snel uitbraken wereldwijd te bestrijden.
Development of a marketable adjuvant candidate for vaccine applications
ADJUVACCINE aims to validate a synthetic platform for scalable production of optimized saponin adjuvants to enhance cost-effective vaccines and attract investment for market entry.
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages
PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.
PReclinical EVAluation and Investigation of Laterocidamide - A novel antibiotic from a new drug class to overcome polymyxin resistance.
Project PREVAIL aims to validate the novel antibiotic Laterocidamide (LATERO) against polymyxin-resistant Gram-negative bacteria, addressing antibiotic resistance while exploring its commercial potential.